Literature DB >> 10725402

Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques.

C D Pauza1, P Trivedi, M Wallace, T J Ruckwardt, H Le Buanec, W Lu, B Bizzini, A Burny, D Zagury, R C Gallo.   

Abstract

The Tat protein is essential for HIV type 1 (HIV-1) replication and may be an important virulence factor in vivo. We studied the role of Tat in viral pathogenesis by immunizing rhesus macaques with chemically inactivated Tat toxoid and challenging these animals by intrarectal inoculation with the simian/human immunodeficiency virus 89.6PD. Immune animals had significantly attenuated disease with lowered viral RNA, interferon-alpha, and chemokine receptor expression (CXCR4 and CCR5) on CD4(+) T cells; these features of infection have been linked to in vitro effects of Tat and respond similarly to extracellular Tat protein produced during infection. Immunization with Tat toxoid inhibits key steps in viral pathogenesis and should be included in therapeutic or preventive HIV-1 vaccines.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10725402      PMCID： PMC16271          DOI： 10.1073/pnas.97.7.3515

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  34 in total

1.  Tat toxoid as a component of a preventive vaccine in seronegative subjects.

Authors:  A Gringeri; E Santagostino; M Muça-Perja; H Le Buanec; B Bizzini; A Lachgar; J F Zagury; J Rappaport; A Burny; R C Gallo; D Zagury
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1999-04-01

Review 2.  The HIV-1 Tat protein: an RNA sequence-specific processivity factor?

Authors:  B R Cullen
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

3.  Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study).

Authors:  A Gringeri; M Musicco; P Hermans; Z Bentwich; M Cusini; A Bergamasco; E Santagostino; A Burny; B Bizzini; D Zagury
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1999-04-01

4.  Pathogenesis of SIVmac251 after atraumatic inoculation of the rectal mucosa in rhesus monkeys.

Authors:  C D Pauza; P Emau; M S Salvato; P Trivedi; D MacKenzie; M Malkovsky; H Uno; K T Schultz
Journal:  J Med Primatol       Date:  1993 Feb-May       Impact factor: 0.667

5.  Cellular uptake of the tat protein from human immunodeficiency virus.

Authors:  A D Frankel; C O Pabo
Journal:  Cell       Date:  1988-12-23       Impact factor: 41.582

6.  Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1.

Authors:  R P Viscidi; K Mayur; H M Lederman; A D Frankel
Journal:  Science       Date:  1989-12-22       Impact factor: 47.728

7.  The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence.

Authors:  G Barillari; R Gendelman; R C Gallo; B Ensoli
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

8.  An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1.

Authors:  R Collman; J W Balliet; S A Gregory; H Friedman; D L Kolson; N Nathanson; A Srinivasan
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

9.  Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120.

Authors:  M O Westendorp; R Frank; C Ochsenbauer; K Stricker; J Dhein; H Walczak; K M Debatin; P H Krammer
Journal:  Nature       Date:  1995-06-08       Impact factor: 49.962

10.  Human immunodeficiency virus type 1 Tat induces apoptosis and increases sensitivity to apoptotic signals by up-regulating FLICE/caspase-8.

Authors:  S R Bartz; M Emerman
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103
View more
  32 in total

1.  Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication.

Authors:  Todd M Allen; Lorenzo Mortara; Bianca R Mothé; Max Liebl; Peicheng Jing; Briana Calore; Marian Piekarczyk; Richard Ruddersdorf; David H O'Connor; X Wang; Chenxi Wang; David B Allison; John D Altman; Alessandro Sette; Ronald C Desrosiers; Gerd Sutter; David I Watkins
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Tat-neutralizing antibodies in vaccinated macaques.

Authors:  Ilia Tikhonov; Tracy J Ruckwardt; Glen S Hatfield; C David Pauza
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

3.  Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1.

Authors:  H Xiao; C Neuveut; H L Tiffany; M Benkirane; E A Rich; P M Murphy; K T Jeang
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

4.  Effects of antibody on viral kinetics in simian/human immunodeficiency virus infection: implications for vaccination.

Authors:  Lei Zhang; Ruy M Ribeiro; John R Mascola; Mark G Lewis; Gabriela Stiegler; Hermann Katinger; Alan S Perelson; Miles P Davenport
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

5.  AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogens.

Authors:  Mauro Pistello; Francesca Bonci; J Norman Flynn; Paola Mazzetti; Patrizia Isola; Elisa Zabogli; Valentina Camerini; Donatella Matteucci; Giulia Freer; Paolo Pelosi; Mauro Bendinelli
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

6.  A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.

Authors:  Thorsten Demberg; Ruth H Florese; Megan J Heath; Kay Larsen; Irene Kalisz; V S Kalyanaraman; Eun Mi Lee; Ranajit Pal; David Venzon; Richard Grant; L Jean Patterson; Birgit Korioth-Schmitz; Adam Buzby; Dilani Dombagoda; David C Montefiori; Norman L Letvin; Aurelio Cafaro; Barbara Ensoli; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

7.  Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection.

Authors:  Ruth H Florese; Roger W Wiseman; David Venzon; Julie A Karl; Thorsten Demberg; Kay Larsen; Leon Flanary; V S Kalyanaraman; Ranajit Pal; Fausto Titti; L Jean Patterson; Megan J Heath; David H O'Connor; Aurelio Cafaro; Barbara Ensoli; Marjorie Robert-Guroff
Journal:  Vaccine       Date:  2008-04-30       Impact factor: 3.641

8.  Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.

Authors:  Laurent Mascarell; Catherine Fayolle; Cécile Bauche; Daniel Ladant; Claude Leclerc
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

9.  Novel biopanning strategy to identify epitopes associated with vaccine protection.

Authors:  Barbara C Bachler; Michael Humbert; Brisa Palikuqi; Nagadenahalli B Siddappa; Samir K Lakhashe; Robert A Rasmussen; Ruth M Ruprecht
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

10.  SIVsm Tat, Rev, and Nef1: functional characteristics of r-GV internalization on isotypes, cytokines, and intracellular degradation.

Authors:  Marinko Sremac; Elizabeth S Stuart
Journal:  BMC Biotechnol       Date:  2010-07-19       Impact factor: 2.563
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.